1. Home
  2. HMR vs MAIA Comparison

HMR vs MAIA Comparison

Compare HMR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HMR

Heidmar Maritime Holdings Corp.

HOLD

Current Price

$1.39

Market Cap

90.3M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.36

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HMR
MAIA
Founded
1984
2018
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.3M
79.0M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
HMR
MAIA
Price
$1.39
$1.36
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
50.8K
328.5K
Earning Date
06-09-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$64.04
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.87
52 Week High
$1.71
$3.19

Technical Indicators

Market Signals
Indicator
HMR
MAIA
Relative Strength Index (RSI) 57.94 48.28
Support Level $1.03 $1.23
Resistance Level $1.71 $1.46
Average True Range (ATR) 0.10 0.05
MACD 0.01 0.00
Stochastic Oscillator 58.82 20.69

Price Performance

Historical Comparison
HMR
MAIA

About HMR Heidmar Maritime Holdings Corp.

Heidmar Maritime Holdings Corp is a commercial and technical management company that operates tanker and dry-bulk vessel pools. The group, along with its subsidiaries, operates as a growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. Its lines of business currently include asset management, tanker pooling, commercial and time charters, assisting clients with the buying and selling of ships, and technical management services for individual vessels, which include assistance in technical operations and crewing of the vessel. Its geographic areas are Singapore, the USA, the Marshall Islands, the United Arab Emirates, Germany, Switzerland, and Other.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: